CNL Strategic Capital, LLC
The company created or modified direct financial obligations or off-balance sheet arrangements, though the specific details are not fully disclosed in the available information.
View raw filing on EDGAR →Filings Radar
SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Franklin BSP Real Estate Debt, Inc.
Franklin BSP Real Estate Debt, Inc. entered into a $125 million Master Repurchase Agreement with Morgan Stanley Bank, N.A., with a three-year initial term and extension options, representing a material new financing arrangement for the REIT's capital structure.
View raw filing on EDGAR →Fundrise eREIT, LLC
The filing discloses a declared daily distribution of $0.0000684930 per share for June 2026, equating to approximately 0.25% annualized yield. While distribution declarations are routine for REITs, this disclosure does not fit cleanly into the standard taxonomy categories (earnings_release, exec_compensation, material_impairment, etc.). The forward-looking language and cautionary statements suggest the Manager is making a material commitment about future distributions, but the core event—a distribution declaration—is administrative rather than a discrete material event like M&A, restatement, or covenant breach. Classified as other_material because it is material to shareholders' investment returns but lacks a more specific event-type match.
View raw filing on EDGAR →GEMAXEL INC
The company amended ARTICLE FIRST of its Certificate of Incorporation to change its legal name from "Worlds Inc." to "Gemaxel Inc." on March 26, 2026. While a name change is a formal corporate action disclosed under Item 5.03, it does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, restatement, auditor change, going concern, impairment, shareholder vote, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, or material litigation). A material name change would affect investor identification and trading of the company's securities, making it material to reasonable investors, though the event itself is primarily administrative in nature.
View raw filing on EDGAR →BUTLER NATIONAL CORP (BUKS)
The disclosure reveals that CEO Christopher J. Reedy is undergoing medical treatment at Mayo Clinic, which could materially affect investor assessment of leadership continuity and operational risk. While the company emphasizes his continued active engagement and the strength of the leadership team, the fact that treatment may "periodically require time away from the office" and the Board's explicit statements of support suggest a material health-related concern about the CEO. This does not fit neatly into exec_departure (he remains CEO) or exec_appointment, but the medical situation and its potential operational implications warrant material disclosure under Item 8.01.
View raw filing on EDGAR →NEXTERA ENERGY INC (NEE-PV)
Florida Power & Light sold $2.25 billion in aggregate principal amount of First Mortgage Bonds across three series (2036, 2056, and 2066 maturities) on June 1, 2026. While this is a material financing event affecting the company's capital structure and debt obligations, it does not fit cleanly into the more specific event categories (not M&A, not a restatement, not a covenant breach, not dilutive equity issuance). The disclosure is routine debt issuance by a regulated utility, filed under Item 8.01 (Other Events) to report transaction documents as exhibits rather than to announce a material corporate event.
View raw filing on EDGAR →OGLETHORPE POWER CORP
The disclosure announces a material debt refinancing: redemption of $297.8 million in aggregate principal amount of First Mortgage Bonds (Series 2014A and 2006) on June 29, 2026, financed by a zero-interest Rural Utilities Service loan under the Inflation Reduction Act that closed May 12, 2026. While this is a significant capital structure event affecting interest expense and financial obligations, it does not fit neatly into the more specific categories (ma_activity typically covers acquisitions/dispositions/mergers; covenant_breach involves violations; dilutive_issuance involves equity). The refinancing is material to investors as it affects the registrant's debt profile, interest costs, and financial position, but the prose centers on a planned debt redemption and refinancing rather than a discrete M&A transaction, impairment, or covenant event.
View raw filing on EDGAR →BRANDYWINE REALTY TRUST (BDN)
The company extended the maturity date of its revolving credit facility from June 30, 2026 to December 30, 2026, a material refinancing action affecting the company's liquidity and debt obligations.
View raw filing on EDGAR →ARRAY DIGITAL INFRASTRUCTURE, INC. (UZD)
The Board declared a special cash dividend of $11.00 per share payable to common and Series A stockholders, likely funded by proceeds from the spectrum asset sale.
View raw filing on EDGAR →SM Energy Co (SM)
SM Energy redeemed $419.2 million in aggregate principal of 6.75% Senior Notes due 2026, satisfying all remaining obligations under the related Indenture Documents. While Item 1.02 covers termination of material definitive agreements, this disclosure is fundamentally about debt redemption and elimination of a material financial obligation rather than a traditional M&A or financing transaction. The event is material to investors as it represents a significant capital deployment and reduction in leverage, but does not fit cleanly into the more specific event categories (ma_activity, covenant_breach, or dilutive_issuance).
View raw filing on EDGAR →O REILLY AUTOMOTIVE INC (ORLY)
The Board approved a $2.0 billion increase to the share repurchase authorization, raising the aggregate program to $31.75 billion with a three-year effective period. While share repurchase programs are capital allocation decisions material to investors' assessment of the company's financial strategy and capital deployment, this disclosure does not fit neatly into the more specific event categories (it is not a dilutive issuance, M&A activity, or executive compensation arrangement). This is best classified as other_material given its significance to shareholder value and financial strategy.
View raw filing on EDGAR →CASELLA WASTE SYSTEMS INC (CWST)
The filing discloses the closing of a $15.0 million remarketing of tax-exempt revenue bonds on June 1, 2026, with a new interest rate of 4.300% per annum through June 1, 2036. While this is a material financing event affecting the Company's debt obligations and cost of capital, it does not fit neatly into the standard 8-K taxonomy categories. The event involves refinancing existing debt rather than a new issuance, acquisition, or other specifically enumerated material event, making "other_material" the most appropriate classification.
View raw filing on EDGAR →SUN COMMUNITIES INC (SUI)
This Item 7.01 disclosure announces an investor presentation and incorporates forward-looking statements regarding a "proposed sale of Park Holidays." While the presentation itself is routine, the repeated references to risks and uncertainties surrounding the Park Holidays sale—including completion risk, operational disruption, and realization of anticipated benefits—signal a material M&A-related event. However, the filing does not explicitly state that a definitive agreement has been signed or that the transaction is imminent; it describes the sale as "proposed," making the precise event type ambiguous. The disclosure is material to investors but does not cleanly fit the ma_activity category (which typically covers entered, completed, or terminated transactions with more specificity).
View raw filing on EDGAR →UFP INDUSTRIES INC (UFPI)
The Board authorized a $300 million share repurchase program expiring April 30, 2027, which is material to investors as it signals capital allocation strategy and potential support for share price. While share repurchases are common corporate actions, a $300 million authorization is substantial enough to affect investor assessment of the company's financial priorities and capital deployment. This does not fit neatly into the more specific event categories (it is not a dilutive issuance, M&A activity, or executive compensation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →TELEPHONE & DATA SYSTEMS INC /DE/ (TDS-PV)
Array's Board declared a special cash dividend of $11.00 per share on June 1, 2026, payable to holders of Common Stock and Series A Common Stock, representing a significant capital distribution to shareholders.
View raw filing on EDGAR →FedEx Freight Holding Company, Inc. (FDXF)
FedEx Freight amended its certificate of incorporation to create 500 million authorized shares of common stock, converted outstanding shares (149.5 million), completely restated its certificate of incorporation and bylaws, and changed its fiscal year end from May 31 to December 31, effective June 1, 2026, as part of the spin-off corporate restructuring.
View raw filing on EDGAR →FedEx Freight Holding Company, Inc. (FDXF)
FedEx Freight adopted a new Code of Conduct and Corporate Governance Guidelines effective upon completion of the spin-off, establishing foundational governance documents for the newly independent company.
View raw filing on EDGAR →FedEx Freight Holding Company, Inc. (FDXF)
FedEx Freight drew down the full $600 million Term Loan Facility on May 27, 2026, to finance a cash dividend payment to its parent company as part of the spin-off transaction.
View raw filing on EDGAR →Voyager Therapeutics, Inc. (VYGR)
Voyager announced FDA clearance of its IND application for VY1706, a tau-targeting gene therapy for Alzheimer's disease, with plans to initiate a clinical trial in H2 2026. This is a material regulatory milestone for a clinical-stage biotech company, but does not fit neatly into the predefined taxonomy—it is neither an earnings release, executive change, M&A activity, nor a negative event like impairment or going concern. The IND clearance represents significant progress in the company's pipeline and would affect a reasonable investor's assessment of the registrant's prospects.
View raw filing on EDGAR →NextCure, Inc. (NXTC)
NextCure disclosed Phase 1 dose escalation data for SIM0505 presented at ASCO 2026, showing a 55% objective response rate in gynecologic cancer patients with a manageable safety profile, along with updated corporate presentation materials reflecting pipeline updates. For a clinical-stage biopharmaceutical company, disclosure of Phase 1 clinical trial data at a major medical conference is material to investors assessing pipeline progress and development trajectory.
View raw filing on EDGAR →Outlook Therapeutics, Inc. (OTLK)
The Company resubmitted a Biologics License Application (BLA) for ONS-5010 to the FDA on June 1, 2026. This is a material regulatory milestone for a biopharmaceutical company's lead candidate, as BLA resubmission represents progress toward potential commercialization and would affect investor assessment of the company's pipeline and prospects. However, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation), so it is classified as other_material.
View raw filing on EDGAR →CECO ENVIRONMENTAL CORP (CECO)
CECO amended its bylaws to increase the maximum board size from nine to ten directors in connection with the merger transaction, facilitating the appointment of two Thermon directors post-closing.
View raw filing on EDGAR →B&G Foods, Inc. (BGS)
B&G Foods disclosed a material debt refinancing activity: a $475 million senior notes offering intended to redeem $509.3 million of existing 5.25% senior notes due 2027. While this resembles debt issuance and refinancing, it does not fit cleanly into the taxonomy's M&A or dilutive issuance categories (which focus on equity or control changes). The disclosure is material to investors assessing the company's capital structure and debt maturity profile, but the event is best classified as other_material given the absence of a dedicated debt refinancing category.
View raw filing on EDGAR →Epsilon Energy Ltd. (EPSN)
The disclosure announces two material corporate actions: a new share repurchase program and a redetermination of the borrowing base. While share repurchases can signal management confidence and affect capital allocation, and borrowing base redetermination may indicate changes in credit facility terms, neither event fits cleanly into the specific taxonomy categories (not a dilutive issuance, not exec compensation, not M&A). The borrowing base redetermination could potentially signal financial stress if reduced, but the filing does not specify the direction or magnitude of change, making it difficult to classify as covenant_breach or other specific event types.
View raw filing on EDGAR →PRINCIPAL FINANCIAL GROUP INC (PFG)
Principal Financial Group issued $400 million in senior notes due 2037 pursuant to a definitive indenture agreement, representing a material debt financing transaction that affects the company's capital structure and leverage.
View raw filing on EDGAR →STEWART INFORMATION SERVICES CORP (STC)
The disclosure announces a quarterly cash dividend of $0.525 per share declared by the Board of Directors. While dividend declarations are routine corporate actions, this is material to investors as it affects shareholder returns and signals the company's capital allocation and financial health. However, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or other defined event types), warranting classification as other_material.
View raw filing on EDGAR →ONCOLYTICS BIOTECH INC (ONCY)
Oncolytics disclosed initial preclinical data for pelareorep in combination with RAS inhibitor modalities and announced plans for additional studies. For a biotech company, preclinical data announcements and new study plans represent material developments in the clinical pipeline that would affect investor assessment of the company's prospects, though the disclosure does not fit the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation).
View raw filing on EDGAR →NEW JERSEY RESOURCES CORP (NJR)
NJNG submitted a base rate case filing with the New Jersey Board of Public Utilities on June 1, 2026, along with related filings for BGSS, CIP, and Energy Efficiency programs. While this is a regulatory filing that could materially affect future utility rates and revenues, it does not fit neatly into the standard 8-K taxonomy (not M&A, not an executive change, not a restatement, etc.). This is disclosed under Item 7.01 (Regulation FD Disclosure) as an investor-relevant regulatory event that warrants classification as other_material.
View raw filing on EDGAR →Hadron Energy, Inc. (GIGGW)
The Amended and Restated Certificate of Incorporation and Bylaws were adopted following the business combination closing, materially modifying shareholder rights through elimination of redemption rights, authorization of new share capital structure, classified board provisions, exclusive forum selection, and transfer restrictions on founder/employee shares.
View raw filing on EDGAR →IN8BIO, INC. (INAB)
IN8bio terminated its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald, which had been a material financing mechanism established in November 2022, eliminating the Company's ability to raise capital through that at-the-market offering program.
View raw filing on EDGAR →MACERICH CO (MAC)
The Company disclosed an investor presentation describing its business and "Path Forward Plan update" via Regulation FD. While the disclosure itself is routine (Item 7.01 furnishing), the substantive content—a strategic plan update—could be material to investors assessing the Company's direction and operational strategy. However, without access to the actual presentation content, the materiality and specific event type cannot be definitively determined; this is classified as other_material pending review of Exhibit 99.1.
View raw filing on EDGAR →Eloxx Pharmaceuticals, Inc. (ELOX)
The company implemented a 1-for-11 reverse stock split and reduced authorized shares from 500 million to 100 million, both approved by stockholders and effectuated via Certificate of Amendment filed May 29, 2026, materially altering the capital structure and per-share metrics.
View raw filing on EDGAR →Eloxx Pharmaceuticals, Inc. (ELOX)
The company disclosed a material modification to the rights of security holders, with details incorporated by reference from Item 5.03 (Amendments to Articles of Incorporation or Bylaws); the specific nature of the modification cannot be determined without access to the referenced Item 5.03 content.
View raw filing on EDGAR →Eikon Therapeutics, Inc. (EIKN)
The company announced updated clinical trial data for drug candidates EIK1001 and EIK1003 presented at ASCO 2026, which is material to investor assessment of the company's pipeline progress and regulatory prospects.
View raw filing on EDGAR →HCI Group, Inc. (HCIIP)
HCI Group entered into comprehensive reinsurance agreements for its four insurance subsidiaries covering June 1, 2026 through May 31, 2027, with total net consolidated reinsurance premiums of approximately $381.2 million to third parties. While this is a material definitive agreement (Item 1.01) involving significant financial commitments and risk transfer arrangements across three reinsurance towers, it does not fit cleanly into the ma_activity category, which typically covers acquisitions, dispositions, mergers, or changes of control. This is a routine but material operational reinsurance placement that would affect investor assessment of the company's catastrophe risk mitigation strategy and financial obligations.
View raw filing on EDGAR →Jade Biosciences, Inc. (JBIO)
Jade Biosciences disclosed interim Phase 1 trial results for JADE101, a novel monoclonal antibody candidate for IgAN treatment, showing favorable safety, potent IgA reductions (approximately 70% at the 700 mg dose), and a differentiated pharmacokinetic profile. The results were presented via conference call and webcast and represent a material clinical development milestone affecting investor assessment of the company's pipeline progress and product viability.
View raw filing on EDGAR →TELEFLEX INC (TFX)
Teleflex announced a $500 million private offering of Senior Notes due 2032 to refinance its 4.625% Senior Notes due 2027, materially affecting the company's capital structure and debt maturity profile.
View raw filing on EDGAR →Strategy Inc (STRD)
Strategy Inc disclosed multiple material operational updates including ATM program activity generating $128.3M in net proceeds, bitcoin sales of $2.5M, dividend declarations across five preferred stock series, and maintenance of an $900M USD Reserve. These disclosures collectively constitute material information about the registrant's financing, asset management, and shareholder distributions.
View raw filing on EDGAR →WELLTOWER INC. (WELL)
Welltower announced an increase in its quarterly common stock dividend from an implied prior level to $0.85 per share, effective Q2 2026. While dividend announcements are material to investors and affect total shareholder return expectations, this disclosure does not fit cleanly into the standard taxonomy categories (earnings_release, exec_compensation, etc.). The announcement is a capital allocation decision rather than a financial result, executive action, or compensation arrangement, making "other_material" the most appropriate classification.
View raw filing on EDGAR →MANHATTAN ASSOCIATES INC (MANH)
Manhattan Associates announced a 6% global headcount reduction with estimated cash charges of $7–9 million in Q2 2026 for severance and termination benefits, representing a material restructuring event affecting the company's cost structure and near-term financial results.
View raw filing on EDGAR →Fulcrum Therapeutics, Inc. (FULC)
Fulcrum announced discontinuation of its pociredir program for sickle cell disease and initiation of a comprehensive strategic review. While this represents a material operational change affecting the company's pipeline and strategic direction, it does not fit neatly into more specific categories (not a restatement, impairment charge, going-concern disclosure, or M&A activity per se). The strategic review language suggests potential future M&A or restructuring, but the disclosed event itself is the program discontinuation and review initiation.
View raw filing on EDGAR →IDEAYA Biosciences, Inc. (IDYA)
IDEAYA disclosed complete Phase 2/3 trial data for darovasertib combination in metastatic uveal melanoma, meeting the primary endpoint with statistically significant PFS improvement (6.9 vs 3.1 months, p<0.0001) and favorable secondary endpoints, representing a significant clinical milestone supporting anticipated NDA filing.
View raw filing on EDGAR →AVIS BUDGET GROUP, INC. (CAR)
Avis Budget issued $300 million in 8.000% Senior Notes due 2031 on May 29, 2026, intending to use proceeds to redeem a portion of its 5.750% Senior Notes due 2027. While this is a material debt issuance and refinancing activity affecting the company's capital structure and financial obligations, it does not fit cleanly into the more specific event categories (ma_activity applies to acquisitions/dispositions, not debt issuances; covenant_breach requires a violation). The disclosure is material to investors as it affects leverage, interest expense, and debt maturity profile, but the primary action is a routine debt offering and refinancing rather than a discrete material event like M&A, impairment, or covenant breach.
View raw filing on EDGAR →Callaway Golf Co (CALY)
Callaway Golf announced full repayment of its Term Loan B, a material debt reduction event that improves the company's financial position and reduces leverage. While this is positive news rather than a distress signal, the complete repayment of a term loan facility is material to investors assessing the registrant's capital structure and financial health. This does not fit neatly into the more specific event categories (not a restatement, covenant breach, going concern, or impairment), making "other_material" the most appropriate classification.
View raw filing on EDGAR →LSB INDUSTRIES, INC. (LXU)
LSB Industries disclosed an acceleration of a previously announced turnaround at its Pryor, Oklahoma facility from July 2026 to immediate commencement on May 28, 2026. While the company states the change in timing should not affect expected duration or cost estimates, the acceleration of a major capital project affecting production capacity and customer commitments is material to investors assessing operational risk and near-term financial performance. This does not fit neatly into the more specific event categories (not M&A, impairment, covenant breach, or litigation), making "other_material" the appropriate classification.
View raw filing on EDGAR →Enviri II Corp
In connection with the spin-off completion, the registrant amended and restated its certificate of incorporation and bylaws, effected a stock split increasing authorized shares, and changed its name from Enviri II Corporation to Enviri Corporation, materially restructuring the post-spin entity's capital stock and governance structure.
View raw filing on EDGAR →OCEANFIRST FINANCIAL CORP (OCFC)
OceanFirst created a new class of preferred stock designated as NVCE Stock via Certificate of Designations filed with Delaware, establishing specific rights, preferences, and conversion terms tied to the Warburg Pincus investment and merger consummation.
View raw filing on EDGAR →Jasper Therapeutics, Inc. (JSPRW)
The Board has initiated a "comprehensive review of strategic alternatives aimed at maximizing shareholder value," which signals potential M&A activity, restructuring, or other transformative corporate actions. While the disclosure does not confirm a specific transaction, the announcement of a formal strategic review is material to investors as it indicates the company is actively considering significant changes to its business structure or ownership. This does not fit neatly into the M&A taxonomy (which typically requires entry into, completion, or termination of a transaction) but is clearly material and warrants classification as other_material pending further developments.
View raw filing on EDGAR →Silo Pharma, Inc. (SILO)
The filing discloses a 1-for-15 reverse stock split effective June 2, 2026, which materially affects the capital structure and share count (from ~16.267 million to ~1.084 million shares outstanding). While reverse splits are sometimes routine capital management actions, this event is material to investors as it affects share price, voting power, and equity award calculations. The disclosure does not fit the more specific event categories (not an earnings release, executive change, M&A, impairment, or delisting notice), making "other_material" the most appropriate classification.
View raw filing on EDGAR →Energy Transition Special Opportunities (ETSS-UN)
The disclosure announces the commencement of separate trading of Class A ordinary shares and Warrants previously bundled in Units, effective June 4, 2026. While this is a routine post-IPO structural event for special purpose acquisition companies (SPACs), it materially affects how investors can trade the underlying securities and represents a significant change in the capital structure's tradability. This does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A activity, or financial restatement), making "other_material" the appropriate classification.
View raw filing on EDGAR →